Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.
| Drug | TSG | SLP (drug target) | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | # |
|---|---|---|---|---|---|---|---|---|---|---|
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | TBX3 | RET | 4 | |||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | TBX3 | RET | 4 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | TBX3 | RET | 3 | |||||||
| futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan | TBX3 | TOP1MT | 3 | |||||||
| lurbinectedin, irinotecan | TBX3 | TOP1MT | 3 | |||||||
| nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone | TBX3 | RXRB | 3 | |||||||
| pembrolizumab, belzutifan, lenvatinib | TBX3 | RET | 3 | |||||||
| regorafenib | TBX3 | RET | 7 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | TBX3 | RET | 2 | |||||||
| alvocidib, paclitaxel | TBX3 | CDK9 | 2 | |||||||
| apatinib, irinotecan | TBX3 | TOP1MT | 2 | |||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | TBX3 | TOP1MT | 2 | |||||||
| asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine | TBX3 | TOP1MT | 2 | |||||||
| bortezomib | TBX3 | PSMB5 | 2 | |||||||
| bryostatin 1, paclitaxel | TBX3 | PRKCE | 2 | |||||||
| cabozantinib | TBX3 | RET | 2 | |||||||
| cabozantinib, atezolizumab, cabozantinib, cabozantinib | TBX3 | RET | 2 | |||||||
| cetuximab, cisplatin, irinotecan, radiation therapy, surgery | TBX3 | TOP1MT | 2 | |||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | TBX3 | RET | 2 | |||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | TBX3 | HDAC3 | 2 | |||||||
| gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a | TBX3 | RET | 2 | |||||||
| inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide | TBX3 | TOP1MT | 2 | |||||||
| irinotecan, capecitabine | TBX3 | TOP1MT | 2 | |||||||
| irinotecan, docetaxel | TBX3 | TOP1MT | 2 | |||||||
| lenvatinib, pembrolizumab | TBX3 | RET | 2 | |||||||
| lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate | TBX3 | RET | 2 | |||||||
| ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab | TBX3 | TOP1MT | 2 | |||||||
| mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a | TBX3 | RET | 2 | |||||||
| pembrolizumab, guadecitabine, mocetinostat | TBX3 | HDAC3 | 2 | |||||||
| pembrolizumab, lenvatinib | TBX3 | RET | 2 | |||||||
| pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu | TBX3 | RET | 2 | |||||||
| pembrolizumab, paclitaxel, docetaxel, irinotecan | TBX3 | TOP1MT | 2 | |||||||
| pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin | TBX3 | RET | 2 | |||||||
| quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery | TBX3 | RET | 2 | |||||||
| regorafenib, laboratory biomarker analysis | TBX3 | RET | 2 | |||||||
| sorafenib, administered orally, ct/mri | TBX3 | RET | 2 | |||||||
| topotecan | TBX3 | TOP1MT | 2 | |||||||
| carfilzomib | TBX3 | PSMB5 | 7 | |||||||
| selpercatinib | TBX3 | RET | 7 | |||||||
| sorafenib | TBX3 | RET | 7 | |||||||
| vandetanib | TBX3 | RET | 7 | |||||||
| 3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat | TBX3 | HDAC3 | 1 | |||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat | TBX3 | HDAC3 | 1 | |||||||
| 5 fluorouracil, leucovorin, irinotecan, oxaliplatin | TBX3 | TOP1MT | 1 | |||||||
| 9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf | TBX3 | TOP1MT | 1 | |||||||
| acetazolamide, temozolomide | TBX3 | CA14 | 1 | |||||||
| actidose aqua, artesunate, amodiaquine | TBX3 | HNMT | 1 | |||||||
| afatinib, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| aldoxorubicin, topotecan | TBX3 | TOP1MT | 1 | |||||||
| alvocidib, docetaxel | TBX3 | CDK9 | 1 | |||||||
| alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis | TBX3 | CDK9 | 1 | |||||||
| aminolevulinic acid | TBX3 | ALAD | 1 | |||||||
| aminolevulinic acid, surgical resection | TBX3 | ALAD | 1 | |||||||
| amrubicin, topotecan | TBX3 | TOP1MT | 1 | |||||||
| andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel | TBX3 | TOP1MT | 1 | |||||||
| ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine | TBX3 | EGLN3 | 1 | |||||||
| at-101, topotecan | TBX3 | TOP1MT | 1 | |||||||
| atezolizumab, cabozantinib | TBX3 | RET | 1 | |||||||
| atorvastatin, temozolomide, radiotherapy | TBX3 | NR1I3 | 1 | |||||||
| avastin, bortezomib | TBX3 | PSMB5 | 1 | |||||||
| avastin, temozolomide, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| avastin, temozolomide, radiation therapy (xrt), irinotecan | TBX3 | TOP1MT | 1 | |||||||
| avelumab, irinotecan, paclitaxel, best supportive care (bsc) | TBX3 | TOP1MT | 1 | |||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | TBX3 | HDAC3 | 1 | |||||||
| azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine | TBX3 | TOP1MT | 1 | |||||||
| bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 | TBX3 | TOP1MT | 1 | |||||||
| bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil | TBX3 | TOP1MT | 1 | |||||||
| berzosertib, computed tomography assisted biopsy, endoscopic biopsy, irinotecan, magnetic resonance imaging | TBX3 | TOP1MT | 1 | |||||||
| bevacizumab [avastin], irinotecan, temozolomide | TBX3 | TOP1MT | 1 | |||||||
| bevacizumab, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging | TBX3 | TOP1MT | 1 | |||||||
| bevacizumab, temozolomide, radiation therapy (xrt), topotecan | TBX3 | TOP1MT | 1 | |||||||
| bevacizumab, temozolomide, vorinostat | TBX3 | HDAC3 | 1 | |||||||
| bi 764532, topotecan, single agent chemotherapy | TBX3 | TOP1MT | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, endoscopic ultrasound, fluorouracil, irinotecan, leucovorin, lymph node biopsy, magnetic resonance imaging, oxaliplatin, pembrolizumab, photodynamic therapy, positron emission tomography, questionnaire administration, verteporfin | TBX3 | TOP1MT | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging | TBX3 | RET | 1 | |||||||
| biospecimen collection, computed tomography, core biopsy, fluorouracil, irinotecan, leucovorin, leucovorin calcium, oxaliplatin, quemliclustat, zimberelimab | TBX3 | TOP1MT | 1 | |||||||
| biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography | TBX3 | RET | 1 | |||||||
| bl-b01d1, irinotecan, paclitaxel, docetaxel | TBX3 | TOP1MT | 1 | |||||||
| bl-b01d1, topotecan | TBX3 | TOP1MT | 1 | |||||||
| bnt327 dose level 1 (dl1), bnt327 dose level 2 (dl2), etoposide, carboplatin, paclitaxel, topotecan | TBX3 | TOP1MT | 1 | |||||||
| bortezomib, carboplatin, paclitaxel | TBX3 | PSMB5 | 1 | |||||||
| bortezomib, gemcitabine hydrochloride | TBX3 | PSMB5 | 1 | |||||||
| bortezomib, irinotecan | TBX3 | PSMB5 | 1 | |||||||
| bortezomib, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| bortezomib, radiation therapy | TBX3 | PSMB5 | 1 | |||||||
| bortezomib, temozolomide, pharmacological study | TBX3 | PSMB5 | 1 | |||||||
| cabozantinib, durvalumab, tremelimumab | TBX3 | RET | 1 | |||||||
| cabozantinib, nivolumab | TBX3 | RET | 1 | |||||||
| cabozantinib, pembrolizumab | TBX3 | RET | 1 | |||||||
| camrelizumab, docetaxel, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| camrelizumab, irinotecan, paclitaxel, paclitaxel-albumin, docetaxel, anlotinib | TBX3 | TOP1MT | 1 | |||||||
| capecitabine, oxaliplatin, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| capecitabine, vorinostat, radiotherapy, surgery to remove tumor | TBX3 | HDAC3 | 1 | |||||||
| carboplatin, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| carboxylesterase-expressing allogeneic neural stem cells, irinotecan, irinotecan hydrochloride, laboratory biomarker analysis, pharmacological study | TBX3 | TOP1MT | 1 | |||||||
| cetuximab, bevacizumab, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| cetuximab, bortezomib | TBX3 | PSMB5 | 1 | |||||||
| cetuximab, irinotecan, oxaliplatin, uft | TBX3 | TOP1MT | 1 | |||||||
| cisplatin, fluorouracil, gemcitabine, irinotecan, leucovorin, nab-paclitaxel, oxaliplatin, radiation therapy | TBX3 | TOP1MT | 1 | |||||||
| cisplatin, gleevec™, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| cisplatin, irinotecan, capecitabine | TBX3 | TOP1MT | 1 | |||||||
| cisplatin, pemetrexed disodium, sorafenib | TBX3 | RET | 1 | |||||||
| digoxin, 5fluorouracil, calcium leucovorin, irinotecan, oxaliplatin | TBX3 | TOP1MT | 1 | |||||||
| durvalumab, oxaliplatin, irinotecan, calcium folinate (leucovorin), fluorouracil, pegylated g-csf | TBX3 | TOP1MT | 1 | |||||||
| eras-007, encorafenib, cetuximab, palbociclib | TBX3 | MAPK8 | 1 | |||||||
| eras-007, encorafenib, cetuximab, palbociclib | TBX3 | LIMK2 | 1 | |||||||
| erdafitinib | TBX3 | RET | 1 | |||||||
| etomidate, midazolam, meperidine | TBX3 | GRIN2B | 1 | |||||||
| everolimus, sorafenib | TBX3 | RET | 1 | |||||||
| fluorouracil, irinotecan, irinotecan hydrochloride, leucovorin, leucovorin calcium, nivolumab, oxaliplatin, therapeutic conventional surgery | TBX3 | TOP1MT | 1 | |||||||
| fluorouracil, leucovorin calcium, oxaliplatin, irinotecan, nivolumab, magnetic resonance imaging, computed tomography, biospecimen collection, questionnaire administration | TBX3 | TOP1MT | 1 | |||||||
| fluorouracil, oxaliplatin, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| gemcitabine, erlotinib, sorafenib | TBX3 | RET | 1 | |||||||
| gemcitabine, nab-paclitaxel, irinotecan, intensity-modulated radiation therapy (imrt) | TBX3 | TOP1MT | 1 | |||||||
| gemcitabine, oxaliplatin, imatinib | TBX3 | RET | 1 | |||||||
| gemcitabine, placebo, sorafenib | TBX3 | RET | 1 | |||||||
| gemcitabine, sorafenib, radiotherapy | TBX3 | RET | 1 | |||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | TBX3 | HDAC3 | 1 | |||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | TBX3 | RET | 1 | |||||||
| gemcitabine, taxotere, xeloda, cisplatin, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| genistein, erlotinib hydrochloride, gemcitabine hydrochloride | TBX3 | ESRRA | 1 | |||||||
| h101, tislelizumab, lenvatinib | TBX3 | RET | 1 | |||||||
| ifinatamab deruxtecan, docetaxel, paclitaxel, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| imatinib, irinotecan, carboplatin | TBX3 | TOP1MT | 1 | |||||||
| imatinib, irinotecan, carboplatin | TBX3 | RET | 1 | |||||||
| irinotecan hydrochloride liposome injection, topotecan | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, 5-fluorouracil, leucovorin | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, bevacizumab, fdopa-pet/mri imaging | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, carboplatin, bevacizumab | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, carboplatin, bevacizumab, radiation | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, carboplatin, bevacizumab, radiation therapy | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, cisplatin, simvastatin | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, ibi343, paclitaxel | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, leucovorin, 5-fluorouracil, docetaxel, cisplatin, leucovorin, 5-fluorouracil | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, lurbinectedin, irinotecan, topotecan, lurbinectedin | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, radiation therapy | TBX3 | TOP1MT | 1 | |||||||
| irinotecan, ramucirumab, blood for angiome profiling, blood for cfdna | TBX3 | TOP1MT | 1 | |||||||
| kc1036, irinotecan, docetaxel, s-1 | TBX3 | TOP1MT | 1 | |||||||
| ketoconazole | TBX3 | NR1I3 | 1 | |||||||
| ko-2806, cabozantinib, adagrasib | TBX3 | RET | 1 | |||||||
| laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat | TBX3 | HDAC3 | 1 | |||||||
| lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil | TBX3 | RET | 1 | |||||||
| lenvatinib, bevacizumab | TBX3 | RET | 1 | |||||||
| liposomal irinotecan, 5-fu, lv, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| ljm716, byl719, paclitaxel, docetaxel, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| lurbinectedin, irinotecan, lurbinectedin, topotecan | TBX3 | TOP1MT | 1 | |||||||
| ly3962673, cetuximab, gemcitabine, nab-paclitaxel, oxaliplatin, leucovorin, irinotecan, 5-fluorouracil | TBX3 | TOP1MT | 1 | |||||||
| mebendazole, vincristine, carboplatin, temozolomide, bevacizumab, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| nab-paclitaxel, gemcitabine, capecitabine, cisplatin, irinotecan, nab-paclitaxel, gemcitabine, capecitabine, cisplatin, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| nab-paclitaxel, gemcitabine, cisplatin, irinotecan, capecitabine, pembrolizumab, olaparib | TBX3 | TOP1MT | 1 | |||||||
| nabiximols, temozolomide, nabiximols-matched placebo | TBX3 | CYP3A7 | 1 | |||||||
| napabucasin, nab-paclitaxel, gemcitabine, nivolumab, paclitaxel, irinotecan, leucovorin, 5fluorouracil, bevacizumab | TBX3 | TOP1MT | 1 | |||||||
| nivolumab, cabozantinib | TBX3 | RET | 1 | |||||||
| np137, oxaliplatin, irinotecan, calcium levofolinate, 5 fu | TBX3 | TOP1MT | 1 | |||||||
| olaparib, temozolomide, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| oxaliplatin, docetaxel, leucovorin, irinotecan, 5-fluorouracil | TBX3 | TOP1MT | 1 | |||||||
| oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, ascorbic acid | TBX3 | EGLN3 | 1 | |||||||
| oxaliplatin, irinotecan, 5-fu, gemcitabine, radiation therapy | TBX3 | TOP1MT | 1 | |||||||
| oxaliplatin, irinotecan, capecitabine | TBX3 | TOP1MT | 1 | |||||||
| oxaliplatin, irinotecan, folinic acid, 5-fluorouracil, gemcitabine, capecitabine | TBX3 | TOP1MT | 1 | |||||||
| oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine | TBX3 | TOP1MT | 1 | |||||||
| oxaliplatin, irinotecan, leucovorin, fluorouracil, laboratory biomarker analysis, flow cytometry, immunohistochemistry staining method, pharmacological study, pf-04136309 | TBX3 | TOP1MT | 1 | |||||||
| oxaliplatin, sorafenib | TBX3 | RET | 1 | |||||||
| oxaliplatine, folinic acid, irinotecan, 5-fu | TBX3 | TOP1MT | 1 | |||||||
| paclitaxel, bryostatin 1 | TBX3 | PRKCE | 1 | |||||||
| paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) | TBX3 | TOP1MT | 1 | |||||||
| paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) | TBX3 | RET | 1 | |||||||
| panitumumab, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| pd-1 inhibitors, irinotecan, capecitabine tablets | TBX3 | TOP1MT | 1 | |||||||
| pegph20, oxaliplatin, leucovorin, irinotecan, 5-fluorouracil | TBX3 | TOP1MT | 1 | |||||||
| pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel | TBX3 | TOP1MT | 1 | |||||||
| pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel | TBX3 | RET | 1 | |||||||
| pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel | TBX3 | RET | 1 | |||||||
| pembrolizumab, vorinostat, temozolomide, radiotherapy | TBX3 | HDAC3 | 1 | |||||||
| pep02, irinotecan, docetaxel | TBX3 | TOP1MT | 1 | |||||||
| pm8002, paclitaxel, topotecan | TBX3 | TOP1MT | 1 | |||||||
| ponatinib | TBX3 | RET | 1 | |||||||
| radiation therapy, temozolomide, sorafenib | TBX3 | RET | 1 | |||||||
| regorafenib, lomustine | TBX3 | RET | 1 | |||||||
| regorafenib, nivolumab, capeox, folfox regimen | TBX3 | RET | 1 | |||||||
| regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil | TBX3 | TOP1MT | 1 | |||||||
| regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil | TBX3 | RET | 1 | |||||||
| regorafenib, temozolomide | TBX3 | RET | 1 | |||||||
| reolysin®, chemotherapy, gemcitabine, irinotecan, leucovorin, 5-fluorouracil, pembrolizumab | TBX3 | TOP1MT | 1 | |||||||
| rmc-6236, gemcitabine, nab-paclitaxel, irinotecan, liposomal irinotecan, 5-fluorouracil, leucovorin, oxaliplatin | TBX3 | TOP1MT | 1 | |||||||
| sacituzumab tirumotecan, trifluridine-tipiracil, irinotecan, paclitaxel, docetaxel, rescue medication, supportive care measures | TBX3 | TOP1MT | 1 | |||||||
| serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome | TBX3 | RET | 1 | |||||||
| shr-a1904, paclitaxel, docetaxel, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| si-b001, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| simmitinib plus irinotecan liposome, irinotecan liposome, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| sirolimus, vandetanib | TBX3 | RET | 1 | |||||||
| sorafenib, erlotinb | TBX3 | RET | 1 | |||||||
| sorafenib, rad001 | TBX3 | RET | 1 | |||||||
| sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide | TBX3 | RET | 1 | |||||||
| surufatinib, irinotecan | TBX3 | TOP1MT | 1 | |||||||
| tace, lenvatinib, combined with tislelizumab group | TBX3 | RET | 1 | |||||||
| tace, tislelizumab, lenvatinib | TBX3 | RET | 1 | |||||||
| tamoxifen citrate, bortezomib | TBX3 | PSMB5 | 1 |